Cardiovascular Safety of Nilotinib in Alzheimer Disease
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
Annals of Neurology - 89(2021), 1, Seite 196-196 |
| Beteiligte Personen: |
Tan, Sean [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 American Neurological Association |
|---|
| Umfang: |
1 |
|---|
| doi: |
10.1002/ana.25947 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001701061 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001701061 | ||
| 003 | DE-627 | ||
| 005 | 20230307110000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ana.25947 |2 doi | |
| 028 | 5 | 2 | |a ANA_ANA25947.xml |
| 035 | |a (DE-627)WLY001701061 | ||
| 035 | |a (WILEY)ANA25947 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.90 |2 bkl | ||
| 084 | |a 44.67 |2 bkl | ||
| 100 | 1 | |a Tan, Sean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Safety of Nilotinib in Alzheimer Disease |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 American Neurological Association | ||
| 700 | 1 | |a Baggio, Diva |4 aut | |
| 700 | 1 | |a Shortt, Jake |4 aut | |
| 700 | 1 | |a Ko, Brian |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of Neurology |g 89(2021), 1, Seite 196-196 |w (DE-627)WLY001695479 |x 15318249 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2021 |g number:1 |g pages:196-196 |g extent:1 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.90 |q ASE |
| 936 | b | k | |a 44.67 |q ASE |
| 951 | |a AR | ||
| 952 | |d 89 |j 2021 |e 1 |h 196-196 |g 1 | ||